Clinical Trial Update: Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assesses iparomlimab plus tovorilimab with bevacizumab and chemotherapy as first-line therapy for advanced malignant mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tovorilimab (Tovorilimab)
• iparomlimab

Snippet

Sponsor: Fudan University | Conditions: Mesothelioma | Phase 2 | Status: NOT_YET_RECRUITING